LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Intellia Therapeutics Inc

Open

SectorHealthcare

9.58 -0.1

Overview

Share price change

24h

Current

Min

9.5

Max

10.05

Key metrics

By Trading Economics

Income

15M

-114M

Sales

3.8M

17M

EPS

-1.1

Profit margin

-687.611

Employees

403

EBITDA

16M

-118M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+208.53% upside

Dividends

By Dow Jones

Next Earnings

7 sie 2025

Market Stats

By TradingEconomics

Market Cap

40M

956M

Previous open

9.68

Previous close

9.58

News Sentiment

By Acuity

50%

50%

154 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Intellia Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 kwi 2025, 09:30 UTC

Top News

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

12 wrz 2024, 17:01 UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 wrz 2024, 11:00 UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Peer Comparison

Price change

Intellia Therapeutics Inc Forecast

Price Target

By TipRanks

208.53% upside

12 Months Forecast

Average 29.65 USD  208.53%

High 65 USD

Low 7 USD

Based on 22 Wall Street analysts offering 12 month price targets forIntellia Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

22 ratings

17

Buy

4

Hold

1

Sell

Technical Score

By Trading Central

7.24 / 8.43Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

154 / 380 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.